Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P48058

UPID:
GRIA4_HUMAN

ALTERNATIVE NAMES:
AMPA-selective glutamate receptor 4; GluR-D; Glutamate receptor ionotropic, AMPA 4

ALTERNATIVE UPACC:
P48058; Q86XE8

BACKGROUND:
The Glutamate receptor 4, known under various names such as AMPA-selective glutamate receptor 4, GluR-D, and Glutamate receptor ionotropic, AMPA 4, is crucial for excitatory synaptic transmission in the central nervous system. It functions as a ligand-gated ion channel, where L-glutamate binding triggers a conformational change, opening the cation channel and facilitating the conversion of a chemical signal into an electrical impulse.

THERAPEUTIC SIGNIFICANCE:
Associated with a neurodevelopmental disorder characterized by developmental delays, intellectual disability, and potential seizures, Glutamate receptor 4's study offers a promising avenue for developing targeted therapies for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.